Enteral bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol)

被引:24
作者
JensenPippo, KE [1 ]
Whitcomb, KL [1 ]
DePrince, RB [1 ]
Ralph, L [1 ]
Habberfield, AD [1 ]
机构
[1] GLAXO INC,RES TRIANGLE PK,NC 27709
关键词
pegylation; recombinant human granulocyte colony stimulating factor; enteral; intraduodenal;
D O I
10.1023/A:1016089503186
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The focus of this paper is to demonstrate that pegylation of a therapeutic protein, recombinant human granulocyte colony stimulating factor (PEG-G-CSF), results in an increase in stability and in retention of in vivo bioactivity when administered by the intraduodenal route and may, therefore, be a suitable form of the protein for inclusion in an oral delivery formulation. Methods. The ability of PEG-G-CSF to elicit a therapeutic response from the enteral route was investigated by two methods of intraduodenal dosing in an in vivo model to determine the optimal dosing method: by slow, constant infusion, or by a single bolus administration. Results. Circulating levels of the proteins confirmed that PEG-G-CSF was delivered into the systemic circulation from the enteral route and that biological activity was retained. Bioavailability from the enteral route by the constant infusion method was calculated from the intravenous administration of the proteins to be between 1.8 and 3.5% while un-modified G-CSF failed to elicit a quantifiable response by this method. Bolus administration of PEG-G-CSF also resulted in biological activity although responses were short lived and significantly lower than with the pegylated formulation. Conclusions. The possible mechanisms of enteral delivery of PEG-G-CSF are discussed. Our results indicate that oral delivery of pegylated G-CSF may be possible and in fact, preferable to using the un-modified form of the therapeutic.
引用
收藏
页码:102 / 107
页数:6
相关论文
共 14 条
  • [1] DELGADO C, 1992, CRIT REV THER DRUG, V9, P249
  • [2] HOLLANDER D, 1989, J LAB CLIN MED, V113, P505
  • [3] PEG 400, A HYDROPHILIC MOLECULAR PROBE FOR MEASURING INTESTINAL PERMEABILITY
    MA, TY
    HOLLANDER, D
    KRUGLIAK, P
    KATZ, K
    [J]. GASTROENTEROLOGY, 1990, 98 (01) : 39 - 46
  • [4] MORSTYN G, 1988, CANCER RES, V48, P5624
  • [5] MURANISHI S, 1990, CRIT REV THER DRUG, V7, P1
  • [6] THE THERAPEUTIC VALUE OF POLY(ETHYLENE GLYCOL)-MODIFIED PROTEINS
    NUCCI, ML
    SHORR, R
    ABUCHOWSKI, A
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1991, 6 (02) : 133 - 151
  • [7] CONTRIBUTION OF SOLVENT DRAG THROUGH INTERCELLULAR-JUNCTIONS TO ABSORPTION OF NUTRIENTS BY THE SMALL-INTESTINE OF THE RAT
    PAPPENHEIMER, JR
    REISS, KZ
    [J]. JOURNAL OF MEMBRANE BIOLOGY, 1987, 100 (02) : 123 - 136
  • [8] PORTER SC, 1985, REMINGTONS PHARMACEU
  • [9] RESISTANCE TO PROTEOLYSIS OF ANTIBODY LIGANDS MODIFIED WITH POLYETHYLENE-GLYCOL
    SADA, E
    KATOH, S
    YAMANAKA, K
    ITAKURA, Y
    [J]. JOURNAL OF FERMENTATION AND BIOENGINEERING, 1991, 71 (02): : 137 - 139
  • [10] CHEMICAL MODIFICATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR BY POLYETHYLENE-GLYCOL INCREASES ITS BIOLOGICAL-ACTIVITY INVIVO
    SATAKEISHIKAWA, R
    ISHIKAWA, M
    OKADA, Y
    KAKITANI, M
    KAWAGISHI, M
    MATSUKI, S
    ASANO, K
    [J]. CELL STRUCTURE AND FUNCTION, 1992, 17 (03) : 157 - 160